Verrica Pharmaceuticals Inc. Comprehensive Income
Verrica Pharmaceuticals Inc. (VRCA) reported Comprehensive Income of -$67.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2024-02-29
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-12-31 was -$24.61M.
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-09-30 was -$24.80M, a 21118.64% decline year-over-year.
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-06-30 was -$10.99M.
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-03-31 was -$6.59M.
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$67.00M.
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$24.46M.
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$35.11M.
- Verrica Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$42.71M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | -$24.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$49.42M derived: sum of 2 quarters · filed 2024-02-29 | -$60.41M derived: sum of 3 quarters · filed 2024-02-29 | -$67.00M 10-K · filed 2024-02-29 | ||
| 2023-09-30 | -$24.80M 10-Q · filed 2023-11-09 | -$35.79M derived: sum of 2 quarters · filed 2023-11-09 | -$42.38M 10-Q · filed 2023-11-09 | -$48.28M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2023-06-30 | -$10.99M 10-Q · filed 2023-08-08 | -$17.58M 10-Q · filed 2023-08-08 | -$23.48M derived: sum of 3 quarters · filed 2024-02-29 | -$23.36M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2023-03-31 | -$6.59M 10-Q · filed 2023-05-09 | -$12.49M derived: sum of 2 quarters · filed 2024-02-29 | -$12.37M derived: sum of 3 quarters · filed 2024-02-29 | -$22.54M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-12-31 | -$5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$5.79M derived: sum of 2 quarters · filed 2024-02-29 | -$15.96M derived: sum of 3 quarters · filed 2024-02-29 | -$24.46M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $118.00K 10-Q · filed 2023-11-09 | -$10.05M derived: sum of 2 quarters · filed 2023-11-09 | -$18.55M 10-Q · filed 2023-11-09 | -$28.12M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$10.17M 10-Q · filed 2023-08-08 | -$18.67M 10-Q · filed 2023-08-08 | -$28.24M derived: sum of 3 quarters · filed 2023-08-08 | -$41.07M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | -$8.50M 10-Q · filed 2023-05-09 | -$18.07M derived: sum of 2 quarters · filed 2023-05-09 | -$30.90M derived: sum of 3 quarters · filed 2023-05-09 | -$42.68M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$9.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$22.40M derived: sum of 2 quarters · filed 2023-03-06 | -$34.18M derived: sum of 3 quarters · filed 2023-03-06 | -$35.11M 10-K · filed 2023-03-06 | ||
| 2021-09-30 | -$12.83M 10-Q · filed 2022-11-07 | -$24.61M derived: sum of 2 quarters · filed 2022-11-07 | -$25.54M 10-Q · filed 2022-11-07 | -$38.52M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-06-30 | -$11.78M 10-Q · filed 2022-08-11 | -$12.71M 10-Q · filed 2022-08-11 | -$25.70M derived: sum of 3 quarters · filed 2022-08-11 | -$36.21M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$934.00K 10-Q · filed 2022-05-09 | -$13.92M derived: sum of 2 quarters · filed 2022-05-09 | -$24.43M derived: sum of 3 quarters · filed 2022-05-09 | -$33.83M derived: sum of 4 quarters · filed 2022-05-09 | ||
| 2020-12-31 | -$12.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$23.49M derived: sum of 2 quarters · filed 2022-03-02 | -$32.89M derived: sum of 3 quarters · filed 2022-03-02 | -$42.71M 10-K · filed 2022-03-02 | ||
| 2020-09-30 | -$10.51M 10-Q · filed 2021-11-12 | -$19.91M derived: sum of 2 quarters · filed 2021-11-12 | -$29.73M 10-Q · filed 2021-11-12 | -$37.38M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | -$9.40M 10-Q · filed 2021-08-10 | -$19.22M 10-Q · filed 2021-08-10 | -$26.86M derived: sum of 3 quarters · filed 2021-08-10 | -$32.96M derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | -$9.82M 10-Q · filed 2021-05-07 | -$17.47M derived: sum of 2 quarters · filed 2021-05-07 | -$23.57M derived: sum of 3 quarters · filed 2021-05-07 | -$30.54M derived: sum of 4 quarters · filed 2021-05-07 | ||
| 2019-12-31 | -$7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$13.74M derived: sum of 2 quarters · filed 2021-03-17 | -$20.72M derived: sum of 3 quarters · filed 2021-03-17 | -$28.17M 10-K · filed 2021-03-17 | ||
| 2019-09-30 | -$6.10M 10-Q · filed 2020-11-09 | -$13.07M derived: sum of 2 quarters · filed 2020-11-09 | -$20.53M 10-Q · filed 2020-11-09 | -$28.11M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | -$6.97M 10-Q · filed 2020-08-05 | -$14.43M 10-Q · filed 2020-08-05 | -$22.01M derived: sum of 3 quarters · filed 2020-08-05 | -$27.93M derived: sum of 4 quarters · filed 2020-08-05 | ||
| 2019-03-31 | -$7.45M 10-Q · filed 2020-05-07 | -$15.04M derived: sum of 2 quarters · filed 2020-05-07 | -$20.95M derived: sum of 3 quarters · filed 2020-05-07 | -$26.27M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | -$7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$13.50M derived: sum of 2 quarters · filed 2020-03-13 | -$18.82M derived: sum of 3 quarters · filed 2020-03-13 | -$20.66M 10-K · filed 2020-03-13 | ||
| 2018-09-30 | -$5.91M 10-Q · filed 2019-11-06 | -$6.75M 10-Q · filed 2018-11-07 | -$11.23M derived: sum of 2 quarters · filed 2019-11-06 | -$13.08M 10-Q · filed 2019-11-06 | -$14.58M 10-Q · filed 2018-11-07 | -$14.51M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | -$5.32M 10-Q · filed 2019-08-07 | -$7.16M 10-Q · filed 2019-08-07 | -$8.60M derived: sum of 3 quarters · filed 2019-08-07 | -$9.96M derived: sum of 4 quarters · filed 2019-08-07 | ||
| 2018-03-31 | -$1.85M 10-Q · filed 2019-05-07 | -$3.28M derived: sum of 2 quarters · filed 2019-05-07 | -$4.64M derived: sum of 3 quarters · filed 2019-05-07 | |||
| 2017-12-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$2.79M derived: sum of 2 quarters · filed 2019-03-07 | -$4.46M 10-K · filed 2019-03-07 | |||
| 2017-09-30 | -$1.36M 10-Q · filed 2018-11-07 | -$3.02M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |